Human Genome Epidemiology Literature Finder
|
Records 1 - 8 (of 8 Records) |
| Query Trace: Breast Neoplasms and FCGR3A[original query] |
|---|
| ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. Oncology 2012 83 (4): 218-27. Kim Ji-Won, Kim Jee Hyun, Im Seock-Ah, Kim Yu Jung, Han Hye-Suk, Kim Jin-Soo, Han Sae-Won, Jeon Yoon Kyung, Oh Do-Youn, Han Wonshik, Kim Tae-You, Park In Ae, Noh Dong-Young, Bang Yung-J |
| Analysis of Fc? receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Jun 18 (12): 3478-86. Hurvitz Sara A, Betting David J, Stern Howard M, Quinaux Emmanuel, Stinson Jeremy, Seshagiri Somasekar, Zhao Ying, Buyse Marc, Mackey John, Driga Adrian, Damaraju Sambasivarao, Sliwkowski Mark X, Robert Nicholas J, Valero Vicente, Crown John, Falkson Carla, Brufsky Adam, Pienkowski Tadeusz, Eiermann Wolfgang, Martin Miguel, Bee Valerie, Marathe Omkar, Slamon Dennis J, Timmerman John |
| Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial. Breast cancer research and treatment 2013 Jun 139 (3): 789-800. Roca Lise, Diéras Véronique, Roché Henri, Lappartient Emmanuelle, Kerbrat Pierre, Cany Laurent, Chieze Stéphanie, Canon Jean-Luc, Spielmann Marc, Penault-Llorca Frédérique, Martin Anne-Laure, Mesleard Christel, Lemonnier Jérôme, de Cremoux Patric |
| Association studies of Fc? receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831. Cancer immunology research 2014 Oct 2 (10): 962-9. Norton Nadine, Olson Rebecca M, Pegram Mark, Tenner Kathleen, Ballman Karla V, Clynes Raphael, Knutson Keith L, Perez Edith |
| FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value? World journal of oncology 2015 Oct 6 (5): 437-440. Botticelli Andrea, Mazzuca Federica, Borro Marina, Mazzotti Eva, La Torre Marco, Bonifacino Adriana, Ciabatta Francesca Romana, Gentile Giovanna, Maddalena Chiara, Simmaco Maurizio, Marchetti Pao |
| Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial. JAMA oncology 2017 Mar 3 (3): 335-341. Gavin Patrick G, Song Nan, Kim S Rim, Lipchik Corey, Johnson Nicole L, Bandos Hanna, Finnigan Melanie, Rastogi Priya, Fehrenbacher Louis, Mamounas Eleftherios P, Swain Sandra M, Wickerham D Lawrence, Geyer Charles E, Jeong Jong-Hyeon, Costantino Joseph P, Wolmark Norman, Paik Soonmyung, Pogue-Geile Kay |
| Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity. JACC. Heart failure 2019 8 7 (9): 795-804. Goel Shom, Liu Jia, Guo Hao, Barry William, Bell Richard, Murray Bronwyn, Lynch Jodi, Bastick Patricia, Chantrill Lorraine, Kiely Belinda E, Abdi Ehtesham, Rutovitz Josie, Asghari Ray, Sullivan Anne, Harrison Michelle, Kohonen-Corish Maija, Beith Ja |
| NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 breast cancer. Breast cancer research : BCR 2019 Dec 21 (1): 133. Jacobs Samuel A, Robidoux André, Abraham Jame, Pérez-Garcia José Manuel, La Verde Nicla, Orcutt James M, Cazzaniga Marina E, Piette Fanny, Antolín Silvia, Aguirre Elena, Cortes Javier, Llombart-Cussac Antonio, Di Cosimo Serena, Kim Rim S, Feng Huichen, Lipchik Corey, Lucas Peter C, Srinivasan Ashok, Wang Ying, Song Nan, Gavin Patrick G, Balousek April D, Paik Soonmyung, Allegra Carmen J, Wolmark Norman, Pogue-Geile Katherine |
- Page last reviewed:Oct 1, 2023
- Page last updated:Dec 04, 2023
- Content source: